A Phase 3, Randomized, Open Label, Controlled Study of Lopinavir/Ritonavir and Lamivudine Versus Standard Therapy in Na?ve HIV-1 Infected Subjects.
Phase of Trial: Phase III
Latest Information Update: 26 Oct 2016
At a glance
- Drugs Lamivudine (Primary) ; Lopinavir/ritonavir (Primary) ; Nucleoside reverse transcriptase inhibitors
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms GARDEL
- 10 Jun 2017 Biomarkers information updated
- 11 Jun 2012 Actual patient number 417 added as reported by ClinicalTrials.gov.
- 11 Jun 2012 Actual end date May 2012 added as reported by ClinicalTrials.gov.